376 related articles for article (PubMed ID: 27197541)
1. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
Lee J; Kefford R; Carlino M
Immunotherapy; 2016 Jun; 8(6):733-46. PubMed ID: 27197541
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.
Abdel-Rahman O
Immunotherapy; 2016 Sep; 8(9):1081-9. PubMed ID: 27485080
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
5. Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.
Loo K; Daud A
Immunotherapy; 2016 Jun; 8(7):775-84. PubMed ID: 27349977
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Pagès C; Baroudjian B; Lebbé C
Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
[TBL] [Abstract][Full Text] [Related]
7. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
Robert C; Soria JC; Eggermont AM
Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 antibodies for melanoma.
Tsai KK; Zarzoso I; Daud AI
Hum Vaccin Immunother; 2014; 10(11):3111-6. PubMed ID: 25625924
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
11. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
12. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
14. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
15. Advances in immunotherapy for melanoma.
Redman JM; Gibney GT; Atkins MB
BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
17. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
[TBL] [Abstract][Full Text] [Related]
20. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]